Orlistat and Foundayo are both taken by mouth, but that shared feature hides major differences. Orlistat is a gastrointestinal lipase inhibitor supplied as OTC Alli 60 mg and prescription 120 mg capsules. Foundayo contains orforglipron, an oral GLP-1 receptor agonist approved by the FDA on April 1, 2026, for long-term weight management in eligible adults with obesity or overweight accompanied by a weight-related condition. It is prescription-only. These are different treatment classes with different safety and medical-access requirements.
Foundayo has a particularly relevant practical distinction from some other oral GLP-1 products: its U.S. instructions permit once-daily administration with or without food and do not impose a special fasting-and-water schedule. That does not make it equivalent to orlistat, whose label links capsules to meals containing fat. This page owns the named Foundayo/orforglipron comparison rather than splitting one U.S. brand into overlapping ingredient and brand articles. For the wider landscape, see oral GLP-1 alternatives to orlistat.
OrliLab independently explains medication and pharmacy access and may earn affiliate fees through disclosed referrals. We do not prescribe, dispense, verify live inventory or promise a particular weight-loss result. A clinician should determine whether any prescription treatment is appropriate after reviewing indication, contraindications, current medicines and tolerability.
The meaningful comparison is oral route plus differences in pharmacology and access. An OTC orlistat product and a new prescription GLP-1 tablet should not be grouped together as if both can be bought without evaluation.
Foundayo’s April 2026 approval makes current U.S. labeling essential. This matrix reports the relevant product identity and patient-facing consequences, not an invented head-to-head efficacy claim.
| Criterion | Orlistat | Foundayo |
|---|---|---|
| Active ingredient | Orlistat | Orforglipron |
| Class | Gastrointestinal lipase inhibitor | Oral GLP-1 receptor agonist |
| U.S. forms | Oral capsules: OTC 60 mg and Rx 120 mg | Prescription oral tablets |
| Label context | Weight management under product-specific labels | Long-term weight management in eligible adults |
| Food instructions | Tied to fat-containing meals as labeled | Once daily with or without food |
| Medical access | OTC label or valid prescription | Prescription and clinical evaluation required |
Foundayo received U.S. approval on April 1, 2026, with labeling for adults with obesity or with overweight plus at least one weight-related comorbid condition, alongside reduced-calorie eating and greater physical activity. The approval concerns the named orforglipron product, not all research-stage oral GLP-1 agents.
The FDA label includes indications, titration rules, contraindications and important warnings. A pharmacy listing should identify the prescribed brand and strength; an active-ingredient description alone is not an adequate substitute for checking the approved product.
Orlistat limits action of gastrointestinal lipases, lowering absorption of some dietary fat. This explains why stool-related adverse effects and guidance about nutrition and vitamins are central to its use.
Orforglipron is a small-molecule GLP-1 receptor agonist affecting appetite and metabolic signaling. Oral administration does not make it work locally in the intestinal lumen like orlistat. The orlistat mechanism guide provides the deeper explanation of fat absorption.
The Foundayo label permits daily oral use with or without food; users do not need to follow the special fasting and water restrictions associated with certain other oral GLP-1 products. This is a label-specific feature and should not be transferred to another medicine simply because both are tablets.
Orlistat capsules follow meal-related instructions. The two medicines also have different product-specific escalation, missed-dose and follow-up considerations. The orlistat and meals guide explains the orlistat food relationship without turning this page into individualized dosing advice.
The U.S. Foundayo label reports randomized, placebo-controlled weight-management trials with outcomes followed through 72 weeks, including populations with and without type 2 diabetes. Orlistat evidence comes from its own clinical programs, including prescription-strength trials with different treatment protocols. Differences in baseline characteristics, background lifestyle treatment, study duration, dose and handling of missing data all matter when interpreting the results.
There is no basis here to manufacture a randomized Foundayo-versus-orlistat outcome or imply a guaranteed degree of weight reduction. For orlistat trial design and findings, use orlistat efficacy evidence.
Foundayo carries a boxed warning about the potential risk of thyroid C-cell tumors associated with GLP-1 receptor agonist activity. The label makes a crucial distinction: unlike GLP-1 agents active in rodents that have produced thyroid C-cell tumors, orforglipron is not pharmacologically active in rats or mice and did not cause tumors in the rodent studies. The human relevance of rodent findings with other GLP-1 receptor agonists remains uncertain. Foundayo is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2, and in those with serious hypersensitivity to the product.
Orlistat has different primary adverse reactions and warnings: oily gastrointestinal effects, vitamin absorption problems, drug interactions and rare kidney injury. A reader should compare specific labels rather than interpret “oral” as a statement of low risk. Orlistat safety information covers its common adverse effects.
OTC Alli 60 mg is available without a prescription to adults who meet its U.S. Drug Facts criteria, while 120 mg orlistat and Foundayo require prescriptions. The presence of an online Foundayo advert does not mean an online store can lawfully supply the medicine without authorized prescribing and a dispensing pharmacy.
The orlistat OTC status guide explains the 60 mg/120 mg boundary. The distinct Foundayo prescription access page covers the named product’s purchasing pathway.
Pricing comparisons should use the actual product, strength, prescription eligibility and insurer benefit rather than a promotional starting price. A new prescription treatment may involve clinical assessment and follow-up alongside pharmacy charges. An OTC capsule has a different reimbursement and checkout framework.
OrliLab does not claim live inventory or current discounts. The orlistat price guide covers evergreen factors, while Foundayo quotes and coverage must be confirmed with the actual plan and pharmacy.
Orlistat can alter absorption of certain medicines and fat-soluble vitamins. Foundayo has different interaction considerations: its U.S. label addresses CYP3A4 inhibitors and inducers, effects on certain other drugs and slower gastric emptying that can alter absorption of oral medicines. The label also calls for extra contraceptive precautions with oral hormonal contraceptives during the 30 days after starting Foundayo and after each dose escalation. These differences require professional medication reconciliation, not a generic claim that one oral medicine has fewer interactions.
Never combine or change weight-management medicines based on a comparison article. Orlistat drug interactions provides a dedicated orlistat reference; clinicians should also examine the current Foundayo label.
Yes. Foundayo is the U.S. prescription brand containing orforglipron, an orally administered GLP-1 receptor agonist. It is not an orlistat product, even though both medicines are taken by mouth.
The FDA approved Foundayo on April 1, 2026, for labeled long-term weight management in eligible adults.
No. Foundayo is a prescription medicine; OTC Alli is a different product containing orlistat 60 mg.
No. Orlistat reduces absorption of some dietary fat, while Foundayo acts as a GLP-1 receptor agonist.
No. The approved U.S. instructions permit Foundayo to be taken once daily with or without food. Unlike certain oral semaglutide products, it has no special fasting-and-water schedule; its other label directions still apply.
No. Orlistat is a lipase-inhibiting capsule; Foundayo is an orforglipron GLP-1 tablet with prescription labeling.
Yes. Foundayo has a boxed warning about the potential risk of thyroid C-cell tumors, but the label specifies that orforglipron itself did not cause tumors in rodent studies. MTC and MEN2 are contraindication contexts.
There is no direct randomized orlistat-versus-Foundayo trial established by the studies discussed here. Each has its own placebo-controlled evidence, with different populations and follow-up; a clinician can explain the practical benefit-risk tradeoffs.
No. Foundayo contains orforglipron and has its own indications, food instructions, warnings and interactions. Other oral GLP-1 medicines, including semaglutide tablets, cannot be substituted or dosed by analogy.
Verify clinical eligibility, the precise prescribed branded tablet, and important warnings and interactions, including any oral contraceptives. The licensed pharmacy should confirm product identity, the prescription, supply and actual patient cost.